Fig. 5

Proportions of Patients Achieving ACR Response Criteria Through 5 Years (NRI). ACR20/50/70, ≥ 20%/50%/70% improvement in American College of Rheumatology response criteria; mono, monotherapy; MTX, methotrexate; NRI, non-responder imputation; QD, once daily; UPA, upadacitinib. ^aPatients in the UPA 30 mg treatment group were later switched to the approved UPA 15 mg dose per protocol amendment. The switch occurred at different visits across the patient population, with the earliest switch occurring at the week 108 visit. Indicated assessments from period 1 (at weeks 4, 12, 24, 36, and 48) are summarized here along with all assessments from the long-term extension. Nominal ^***P < .001, ^**P < .01, and ^*P < .05 for upadacitinib 15 mg versus MTX. Nominal ^###P < .001, ^##P < .01, and ^#P < .05 for upadacitinib 30 mg versus MTX